Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Boom, .17 break will be huge!
$OTLC Huge volume clearing out .17!
Nice dip opportunity..I doubt it lasts..
Looks like OTLC is giving some cheap shares out this morning
Some great catalysts in there. Love the Price target.
Check out the $OTLC pipeline, we could hear an update any time on a number of fronts
https://www.oncotelic.com/pipeline/
I agree with you there..should trade strong to .20 when it does IMO
Today .17 has to be the goal on OTLC it really needs to fall
$OTLC Accumulation on the chart is really starting to catch my eye as volume has been on the rise here..
https://stockcharts.com/c-sc/sc?s=OTLC&p=D&b=5&g=0&i=t9568513346c&r=1640775158378
Strong buys eod and overall for that matter today..looks ready to test .20 IMO…
They've been holding it back pretty good here today but I think if we get any kind of major catalyst this will pop.
Looks like todays seller is about done
Strong loading here..on above average volume..gaining strength here!
just one MM left at .1699 then .19 is up next on L2
$OTLC just flipped green..
Ask cleared! About to go green here..
Their PR from December 2nd mentioned their mesothelioma drug going into phase 2 trials so I would expect some follow-up on that as well in the coming weeks. Something else to watch out for. They definitely have a lot in the pipeline here.
Look at those bids at .16!
big conference presentation Jan 25-27 for OTLC, there is usually big news released ahead of these types of things - something to keep an eye on
https://www.otcmarkets.com/stock/OTLC/news/Oncotelics-Dr-Anthony-Maida-to-Present-at-2nd-Annual-TGF--for-Immuno-Oncology-Drug-Development-Summit-in-January-2022?id=335678
love that bid in at .16
Some early fills here into stronger hands..
$OTLC strong day yesterday and lighter volume, would love to see this break .17 and 18 today https://schrts.co/tZbwyJmJ
$OTLC Strong buys we’re picking up during the afternoon..strong Covid play..
Strong day here..
$OTLC Up 8 percent now as ask is getting cleared..
It looks great today. Steady climb but not super fast.
$OTLC bidders continue to move up and take shares..trading very well here..
I keep getting and setting new alerts as this goes higher today.
$OTLC Strong buys just cleared the ask..just a few more slaps to .20 it looks like..
I agree with your assessment. I think we're going to see a big first quarter here.
Was looking over the news of this..would not be at the conference if some strong updates were not coming ..just my thoughts..
Looks thin to .20..just a spark sends it..
big conference presentation Jan 25-27 for OTLC, there is usually big news released ahead of these types of things - something to keep an eye on
https://www.otcmarkets.com/stock/OTLC/news/Oncotelics-Dr-Anthony-Maida-to-Present-at-2nd-Annual-TGF--for-Immuno-Oncology-Drug-Development-Summit-in-January-2022?id=335678
Just saw OTLC getting talked about again. Is this our week?
Yup..bidders continue to move higher looking to get filled..
love seeing the spread tightening up .16 x .17 now
$OTLC Sure is..nice to see this company start to get noticed..Covid play here that should be on people’s watchlist..
Nice Cross over the 10 and 20ma here.
$OTLC Bidders moving up now..trading very healthy today…
Yup..ask cleared out in a hurry..ask looks so thin moving higher..
Some nice buys picking up here.
$OTLC trading between the 50 and 200 DMA, which one breaks first? banking on the 200 DMA with all the great news in the pipeline https://schrts.co/NzgqJXyP
Strong bids in place..looking for a nice push up from that…
Share structure looks good. It looks like it's going into a tightening wedge on the six month chart. Riding just above the 20MA.
Was looking at the news over the weekend..ss is sound as well..
OTLC
Oncotelic Therapeutics, Inc.
Common Stock
0.155
0.00
0.00%
0.146 / 0.155 (21500 x 5000)
Real-Time Best Bid & Ask: 09:54am 12/27/2021
Delayed (15 Min) Trade Data: 09:30am 12/27/2021
Overview
Quote
Company Profile
Security Details
News
Financials
Disclosure
Research
OTLC SECURITY DETAILS
Share Structure
Market Cap Market Cap
57,934,171
12/23/2021
Authorized Shares
750,000,000
12/14/2021
Outstanding Shares
373,768,843
12/14/2021
Restricted
Not Available
Unrestricted
Not Available
Held at DTC
62,609,364
12/14/2021
Float
170,974,294
08/09/2021
Par Value
0.01
hug news from last week, these guys seem to be ahead of the curve on covid research and treatments!!
https://www.otcmarkets.com/stock/OTLC/news/ONCOTELIC-ANNOUNCES-THAT-ORF8-MUTATIONS-ARE-DRIVING-THE-EVOLUTION-OF-THE-DELTA-AND-THE-OMICRON-VARIANTS?id=336776
“It is gratifying to identify what we think is the fundamental evolutionary pathway for SARS-CoV-2,” said Dr. Vuong Trieu, CEO and Chairman of Oncotelic. “The analysis allows us to position our therapeutic and vaccine platform against ORF8 to address this pandemic as it further mutates.”
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
956
|
Created
|
08/23/16
|
Type
|
Free
|
Moderators |
Oncotelic is actively seeking collaborations with corporations, academic institutions, and patient groups to advance our programs.
We have a history of successful partnerships and welcome new collaboration and licensing opportunities.
Interested parties may contact:
Chulho Park PhD, Chief Technology Officer
Oncotelic Inc.
29397 Agoura Rd., Suite 107
Agoura Hills, CA 91301
bd@oncotelic.com
(650) 635-7000
Through our history of collaborative research, Mateon has supported clinical research projects in the United Kingdom (UK) led by
Cancer Research UK (CRUK) along with additional academic partners.
Currently, we are supporting the PAZOFOS study (NCT02055690), which is being led by The Christie Hospital NHS Foundation Trust
and coordinated by the Manchester Academic Health Science Centre,
Trials Coordination Unit, or MAHSC-CTU, with additional support from The University of Manchester, the Royal Marsden NHS Foundation Trust,
and Mount Vernon Cancer Centre (part of the East and North Hertfordshire NHS Trust).
This Phase 1b/2 study is evaluating the combination of CA4P (fosbretabulin) with the tyrosine kinase inhibitor pazopanib (Votrient®) versus pazopanib
alone for the treatment of advanced recurrent ovarian cancer.
We are providing CA4P for use in this trial.
Continuing in our history of collaborative research, Mateon is providing investigational drug to the Markey Cancer Center for their study Study MCC-2016-08 (NCT03014297).
The study is designed as a single center, open label, phase 1 clinical trial for patients with grade 1-3 gastroenteropancreatic neuroendocrine tumors.
In the first part of the study, up to 15 patients will be treated with everolimus in combination with two different dosing regimens of
CA4P to establish appropriate CA4P dosing levels and evaluate the safety of the drug combination.
The second part of the study is designed to enroll 15 additional patients for assessment of additional safety and efficacy data.
Patients enrolled in MCC-2016-088 will be treated with CA4P and everolimus for 12 weeks.
We are committed to leveraging our intellectual property and the product development expertise of our highly experienced management team to enable
vascular targeted therapy to realize its true potential and to bring much needed new therapies for orphan oncology indications to cancer patients worldwide.
We have a portfolio of preclinical and clinical stage candidates focused on areas of significant unmet need that we believe can bring significant value to our shareholders.
Our common stock is traded on the OTCQB Market under the symbol “MATN”.
We are headquartered in Agoura Hills, California
https://www.oncotelic.com/pointr-data/
EdgePoint AI was established in order to advance the company’s revolutionary cluster-computer platform for AI that processes machine learning
models at a fraction of the power and budget of mainstream computing in pharmaceutical manufacturing.
The company’s technology solution “TrustPoint” provides an AI computing platform for pharmaceutical and healthcare verticals
including blockchain support for manufacturing where data integrity and security are of utmost importance.
EdgePoint is composed of a team of executives with pharmaceutical drug development, GMP manufacturing and deep AI knowledge.
The team includes Steven King who was the former CEO of Peregrine Pharmaceuticals, Inc. (NASDAQ) and its wholly-owned
contract biomanufacturing subsidiary Avid Bioservices, Inc., for over 15 years, during which time the company advanced its
lead compound through Phase 3 development, while growing revenues to over $55 million;
Seasoned executive, Saran Saund who has been founder, CEO and GM at several startups and public companies for which he returned
significant value to shareholders in his startups and chief technology officer; Burcak Beser who has been founder and
CTO of several successful private and public companies with over 144 patents during his career; and Lisa Stepp with broad experience in
executive leadership across geographies and in all aspects of drug development and program management.
The core technology platform for EdgePoint AI came from PointR -which was acquired by Mateon in Nov 2019. Examples of PointR capabilities are shown below.
http://oncotelic.com/wp-content/uploads/LosAngelesBusinessJournal2018-05-21.pdf
Health Care: Drug Developer Adds Digital Monitor
TWO YEAR CHART: NASDAQ
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |